Immunogenicity of the BA.1 and BA.4/BA.5 SARS-CoV-2 Bivalent Boosts: Preliminary Results from the COVAIL Randomized Clinical Trial.
Angela R BrancheNadine G RouphaelCecilia LosadaLindsey R BadenEvan J AndersonAnne F LuetkemeyerDavid J DiemertPatricia L WinokurRachel M PrestiAngelica C KottkampAnn R FalseySharon E FreyRichard RuppMartín BäckerRichard M NovakEmmanuel B WalterLisa A JacksonSusan J LittleLilly C ImmergluckSiham M MahgoubJennifer A WhitakerTara M BabuPaul A GoepfertDahlene N FuscoRobert L AtmarChristine M PosavadAntonia NetzlDerek J SmithKalyani TeluJinjian MuMat MakowskiMamodikoe K MakheneSonja CrandonDavid C MontefioriPaul C RobertsJohn H BeigelPublished in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2023)
In a randomized clinical trial, we compare early neutralizing antibody responses after boosting with bivalent SARS-CoV-2 mRNA vaccines based on either BA.1 or BA.4/BA.5 Omicron spike protein combined with wildtype spike. Responses against SARS-CoV-2 variants exhibited the greatest reduction in titers against currently circulating Omicron subvariants for both bivalent vaccines.